Fig. 1.
A RT-PCR standard curve by plotting the threshold cycle (Cq) versus the number of C. albicans ATCC10231 (CFU/g). The DNA was amplified with the primers labeled with FAM.
Table I
Baseline patient characteristics.
| Characteristics | Biologic therapy – IFX (n = 13) | EEN (n = 48) | Control group (n = 17) |
|---|---|---|---|
| Male:Female, n (%) | 7 (54%):6 (46%) | 29 (60%):19 (40%) | 9 (53%):8 (47%) |
| Age at diagnosis, months; mean (± SD) | 137 (± 48.15) | 160.27 (± 37.11) | N/A |
| Age at initial treatment, months; mean (± SD) | 157.15 (± 45.16) | 160.27 (± 37.11) | N/A |
| Weight, kg; mean (± SD) | 41.97 (± 16.3) | 40.93 (± 14.05) | 42.8 (± 17.2) |
| Height, cm; mean (± SD) | 149.95 (± 20.31) | 155.3 (± 19.1) | 148.7 (± 18.8) |
| BMI, kg/m2; mean (± SD) | 17.89 (± 3.62) | 16.4 (± 2.92) | 18.3 (± 3.8) |
| PCDAI-1; mean (± SD) | 47.5 (± 16.43) | 32.03 (± 15.01) | N/A |
| PCDAI-2; mean (± SD) | 9.04 (± 6.5) | 5.93 (± 11.36) | N/A |
Fig. 2.
Quantitative assessment of fungi of the genus Candida using qPCR in the stool of patients with CD before and after biologic (IFX) and exclusive enteral nutrition (EEN) treatments and control group.
a – significant differences between children with CD and the control group; b – significant differences between children with CD before and after biologic treatment.